December 2016 - Page 25 of 30

TuesdayDec 06, 2016 1:00 pm

PCM (PCMI) Starts Presentation at LD Micro Main Event

PCM (NASDAQ: PCMI) is a multi-vendor provider of technology products and solutions, and consumer products. The company primarily sells device products, servers, storage products, networks, printers and related accessories and devices. It also provides value-added services, such as custom configured systems, software licensing asset management, image management, product asset tagging, and asset disposal services, as well as software value-added reseller services, managed services, cloud-based services, consulting, and IT management and related services. For more information, visit the company's website at www.pcm.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social…

TuesdayDec 06, 2016 1:00 pm

Ener-Core (ENCR) Starts Presentation at LD Micro Main Event

Ener-Core (OTC: ENCR) designs, develops and manufactures products that are based on power oxidizer technologies. The company's proprietary technology provides an alternative to traditional methods of destroying gaseous pollution by enabling industrial facilities to generate on-site power from their waste gases. Its products include Ener-Core PowerStation EC250 and Ener-Core Powerstation KG2-3G/GO, which have applications in landfills, distilleries, and wastewater treatment plants, as well as various industrial processes. For more information, visit the company's website at www.ener-core.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted…

TuesdayDec 06, 2016 1:00 pm

Fusion Telecommunications (FSNN) Starts Presentation at LD Micro Main Event

Fusion Telecommunications (NASDAQ: FSNN) provides integrated cloud solutions to small, medium and large businesses. The company's advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud communications, cloud connectivity, and cloud computing. Fusion's innovative, yet proven cloud solutions are designed to lower the cost of ownership, and deliver new levels of security, flexibility, scalability, and speed of deployment. For more information, visit the company's website at www.fusionconnect.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news…

TuesdayDec 06, 2016 1:00 pm

IntelliPharmaCeutics International (IPCI) Starts Presentation at LD Micro Main Event

IntelliPharmaCeutics International (NASDAQ: IPCI) is a pharmaceutical company that engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. For more information, visit the company's website at www.intellipharmaceutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release…

TuesdayDec 06, 2016 12:37 pm

Cellceutix Corp. (CTIX) Advances Pipeline toward Multi-billion Dollar Opportunities, Piques Peer Interest along the Way

Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several key markets. Advancements of its current pipeline – spanning dermatology, cancer, infectious disease and gastrointestinal indications – also set the company on course to achieve another season of remarkable progress. Cellceutix’s lead cancer drug candidate is Kevetrin™, an Orphan Drug anti-cancer agent entering phase 2a clinical trials for the treatment of ovarian cancer. Upon commercialization, Kevetrin would be the world’s…

TuesdayDec 06, 2016 12:30 pm

Citius Pharmaceuticals (CTXR) Starts Presentation at LD Micro Main Event

Citius Pharmaceuticals (OTC: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products. The company has a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. By using previously approved drugs with substantial safety and efficacy data, the company seeks to reduce the risks associated with pharmaceutical product development and regulatory requirements, and focuses on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, visit the company's website at www.citiuspharma.com. About NetworkNewsWire NetworkNewsWire (NNW)…

TuesdayDec 06, 2016 12:30 pm

New Age Beverages (NBEV) Starts Presentation at LD Micro Main Event

New Age Beverages (OTC: NBEV) is a healthy functional beverage company originally founded in 2003, which in 2016 re-created via the combination of XingTea®, Aspen Pure® Artesian Water, Búcha® Live Kombucha, and New Age Beverages. The company competes in several segments, including ready to drink (RTD) tea, RTD coffee, kombucha, energy drinks, relaxation drinks and functional waters. The company's portfolio also includes Marley One Drop® RTD Coffee and Marley Mellow Mood™ Relaxation Drinks. The brands are sold in 46 states within the U.S. and in more than 10 countries internationally across all channels via direct and store door distribution systems.…

TuesdayDec 06, 2016 12:30 pm

BioCorRx (BICX) Starts Presentation at LD Micro Main Event

BioCorRx (OTC: BICX) is a healthcare solutions company focused on improving the lives of those struggling with alcohol and opioid addiction. Designed to treat alcoholism and certain opioid addictions, the BioCorRx® Recovery Program is used by a network of independently owned and operated treatment centers located throughout the United States. The program consists of a proprietary long-lasting implant of the FDA approved medication, naltrexone, which is proven to substantially reduce cravings for drugs and alcohol. It is a high-quality, comprehensive and cost- effective recovery program built on a strong foundation of experience and practice, allowing for an improved quality of…

TuesdayDec 06, 2016 12:30 pm

Lightbridge (LTBR) Starts Presentation at LD Micro Main Event

Lightbridge (NASDAQ: LTBR) is a nuclear fuel technology company that operates in two segments: technology and consulting. The company offers all-metal fuel for operating and new build reactors; all-uranium seed and blanket fuel for existing plants and new build reactors; and thorium-based seed and blanket fuel for existing and new build reactors. The company's services include integrated strategic advice across a range of areas, including regulatory development, nuclear reactor site selection, procurement and deployment, reactor and fuel technology, international relations, program management, regulatory affairs, and infrastructure development. For more information, visit the company website at www.ltbridge.com. About NetworkNewsWire NetworkNewsWire (NNW)…

TuesdayDec 06, 2016 12:30 pm

Hemispherx Biopharma (HEB) Starts Presentation at LD Micro Main Event

Hemispherx Biopharma (NYSE: HEB) is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. The company's flagship products include Alferon N Injection® and the experimental therapeutics Rintatolimod (tradenames Ampligen® or Rintamod®) and Alferon® LDO. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. For more information, visit the company's website at www.hemispherx.net. About NetworkNewsWire NetworkNewsWire (NNW)…